Aztreonam and Ceftazidime-Avibactam Administration During Hemodialysis
Both aztreonam and ceftazidime-avibactam (Zaviceft) should be administered immediately after each hemodialysis session, not during dialysis, to prevent premature drug removal and maintain therapeutic concentrations throughout the 48–72 hour interdialytic interval. 1
Timing of Administration
- Administer both antibiotics after dialysis sessions to ensure the full dose remains in circulation for the entire interdialytic period, preventing subtherapeutic levels that lead to treatment failure 1, 2
- Never administer before or during dialysis, as this results in significant drug removal—hemodialysis removes 38.2% of aztreonam in 4 hours and >50% of avibactam during a dialysis session 3, 4
- Post-dialysis administration facilitates directly observed therapy and avoids drug loss during the dialysis process 2
Specific Dosing Regimens for Thrice-Weekly Hemodialysis
Aztreonam
- Loading dose: Standard dose (typically 2 g IV) as initial therapy 3
- Maintenance: One-fourth the loading dose (500 mg) at standard intervals between dialysis sessions 3
- Supplemental dose: Half the usual maintenance dose (250 mg) immediately after each dialysis session 3
- Aztreonam serum half-life extends from 2.7 hours during dialysis to 7.9 hours in the interdialytic period 3
Ceftazidime-Avibactam (Zaviceft)
- Dose adjustment required based on creatinine clearance, maintaining the 4:1 ratio of ceftazidime:avibactam 4, 5
- For patients on hemodialysis: Administer after each dialysis session with appropriate renal dose reduction 4
- The approved regimen achieves 89% to >99% joint probability of target attainment across renal function groups when given as 3-hour IV infusions 6
- Prolonged infusion (3 hours) is associated with improved 30-day survival and should be used when feasible 7
Combination Therapy: Aztreonam + Ceftazidime-Avibactam
- This combination is specifically indicated for MBL-producing carbapenem-resistant Enterobacterales (CRE), particularly NDM and VIM producers 7
- The combination demonstrated significantly lower 30-day mortality (HR 0.37,95% CI 0.13–0.74) compared to other therapies for MBL-producing CRE bacteremia 7
- Ceftazidime in the combination does not affect aztreonam-avibactam MICs—all tested isolates showed MICs within one 2-fold dilution regardless of ceftazidime concentration 8
- Both drugs should be administered after dialysis using their respective adjusted doses 1, 3, 4
Critical Dosing Principles
- Maintain standard individual doses while extending the dosing interval—never reduce individual doses, as this produces subtherapeutic peak concentrations and treatment failure 1
- Both aztreonam and avibactam exhibit concentration-dependent bactericidal activity requiring adequate peak levels 1, 5
- The fundamental error is reducing individual doses rather than extending intervals, which leads to inadequate drug exposure 1
Therapeutic Drug Monitoring
- Consider TDM for both agents to verify adequate exposure without excessive accumulation, especially in critically ill patients 1, 2
- Measure trough concentrations immediately before the next dialysis session to confirm therapeutic levels during the 48–72 hour interdialytic gap 1
- The relationship between urea clearance and aztreonam clearance (CLaztreonam/CLurea ratio 0.28–0.33) can guide dose adjustments 3
Common Pitfalls to Avoid
- Do not use daily dosing schedules—this leads to drug accumulation and potential toxicity 1
- Avoid administering during dialysis—both drugs are significantly removed by hemodialysis, resulting in subtherapeutic levels 3, 4
- Do not reduce individual doses—extend the interval instead to maintain efficacy 1
- For ceftazidime-avibactam, ensure appropriate renal adjustment to maintain the 4:1 ratio, as both components require similar dose modifications 4, 5